-> Home    -> Contact Us    -> Site Map   
  -> Search
ImmunoGen, Inc.

Company OverviewOur TAP TechnologyProduct PipelineInvestor InformationJoin Our Team
Product Pipeline

There are a number of novel anticancer compounds already in clinical testing that make use of our TAP technology. Several of these target common cancers, such as HER2+ breast cancer, non-Hodgkin's lymphoma and multiple myeloma. Our TAP technology is poised to be the first antibody-drug conjugate (ADC) technology to be used for the treatment of widely occurring cancers.


Clinical-Stage Compound
Phase I
Phase II
Pivotal
Phase II /
Phase III
T-DM1      
     3rd-line HER2+ MBC
     2nd-line HER2+ MBC
     1st-line HER2+ MBC
     Combination trials in MBC
     Adjuvant trials under consideration
IMGN901      
     Multiple myeloma monotherapy
     Multiple myeloma combination
     Solid tumors
IMGN388* - solid tumors
SAR3419 - non-Hodgkin's lymphoma
BIIB015 - solid tumors
BT-062** - multiple myeloma
Earlier stage - multiple      

Roche/Genentech
Wholly-owned by ImmunoGen
sanofi-aventis
Biogen Idec
Biotest

MBC = metastatic breast cancer
*Centocor has opt-in rights
**ImmunoGen has opt-in rights


© 2010 ImmunoGen, Inc. | Privacy Policy | Usage Policy